Compare Manulife Financial Corporation (MFC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs 10X Genomics Inc — how do they compare? Manulife Financial Corporation trades at $42.32 (market cap $69.48B), while 10X Genomics Inc trades at $82.09 (market cap $10.07B). The key difference: Manulife Financial Corporation is far larger — about 6.9× 10X Genomics Inc's market cap, and Manulife Financial Corporation pays a 3.23% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 119 Days and 10X Genomics Inc for 92 Days on average.
| MFC | TXG | |
|---|---|---|
Market Cap | $69.48B | $10.07B |
Volume | 1,347,508 | 5,657,286 |
Sector | Financials | Health |
52-Week High | $44.77 | $97.74 |
52-Week Low | $31.64 | $11.48 |
Typical Hold Time | 119 Days | 92 Days |
Enterprise Value | $64.75B | $9.59B |
Dividend Yield | 3.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $41.67, down 2.94% on the day, with a bearish technical signal from moving averages and oscillators. Revenue grew to $53.01B in 2025, with net income of $5.78B and a P/E of 16.22. Recent news includes a new $750M subordinated notes offering and executive appointments, while institutional investors like Bank of America added positions in Q2 2026.
The outlook is mixed: analyst consensus is Buy with a $34.24 target, but technicals suggest near-term pressure. Upside drivers include strong insurance sales and Asia growth, while risks involve premium valuation and macroeconomic sensitivity. Cash flow trends show improved operations, but net cash flow declined in 2025.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
